Anticancer drug discovery using chemical genomics

Area of Science:

• Oncology
• Pharmacology
• Genomics

Background:

• Cancer remains a leading global cause of death.
• Current drug discovery and development for cancer therapeutics averages 15 years, delaying patient benefit.
• The vast amount of genomics and proteomics data presents challenges in identifying viable drug targets.

Purpose of the Study:

• To introduce chemical genomics as an emerging field to accelerate cancer drug discovery and development.
• To highlight the need for integrated tools and technologies to shorten development timelines and mitigate late-stage clinical trial failures.
• To emphasize the early integration of biological and chemical approaches for informed decision-making.

Main Methods:

• Utilizing tools and technologies from biology and chemistry in a parallel and cyclic manner.
• Integrating advancements from combinatorial chemistry, informatics, synthesis, cell-based assays, microarrays, genomics, and proteomics.
• Applying chemical genomics principles early in the drug development process.

Main Results:

• Chemical genomics aims to significantly reduce the pre-clinical development time for cancer therapeutics.
• The field seeks to decrease the risk of late-stage clinical drug failure through early, informed decisions.
• Accelerated identification and validation of potential drug targets.

Conclusions:

• Chemical genomics offers a promising approach to expedite the delivery of novel cancer therapeutics to patients.
• Early integration of diverse technological tools is crucial for efficient and successful drug development.
• Smart decision-making, facilitated by chemical genomics, can overcome current limitations in cancer drug discovery.